223 related articles for article (PubMed ID: 18090405)
1. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
[TBL] [Abstract][Full Text] [Related]
2. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Avihingsanon A; Lewin SR; Kerr S; Chang JJ; Piyawat K; Napissanant N; Matthews GV; Dore GJ; Bowden S; Lange J; Ruxrungtham K
Antivir Ther; 2010; 15(6):917-22. PubMed ID: 20834105
[TBL] [Abstract][Full Text] [Related]
4. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Ratcliffe L; Beadsworth MB; Pennell A; Phillips M; Vilar FJ
AIDS; 2011 May; 25(8):1051-6. PubMed ID: 21346511
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Butt AA
AIDS Read; 2006 Apr; 16(4):219-22. PubMed ID: 16617931
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
Soriano V; Mocroft A; Peters L; Rockstroh J; Antunes F; Kirkby N; de Wit S; Monforte Ad; Flisiak R; Lundgren J;
J Antimicrob Chemother; 2010 Mar; 65(3):548-55. PubMed ID: 20051475
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
de Vries-Sluijs TE; Reijnders JG; Hansen BE; Zaaijer HL; Prins JM; Pas SD; Schutten M; Hoepelman AI; Richter C; Mulder JW; de Man RA; Janssen HL; van der Ende ME
Gastroenterology; 2010 Dec; 139(6):1934-41. PubMed ID: 20801123
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of cirrhosis in HIV/HBV coinfection.
Mallet VO; Dhalluin-Venier V; Verkarre V; Correas JM; Chaix ML; Viard JP; Pol S
Antivir Ther; 2007; 12(2):279-83. PubMed ID: 17503671
[TBL] [Abstract][Full Text] [Related]
10. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Schirmer P; Winters M; Holodniy M
J Clin Virol; 2011 Nov; 52(3):261-4. PubMed ID: 21840252
[TBL] [Abstract][Full Text] [Related]
11. Special considerations and treatment of patients with HBV-HIV coinfection.
Dieterich DT
Antivir Ther; 2007; 12 Suppl 3():H43-51. PubMed ID: 18284182
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
13. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
14. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of chronic hepatitis B in HIV co-infected patients].
Massard J; Benhamou Y
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606
[TBL] [Abstract][Full Text] [Related]
16. Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine.
Mondou E; Sorbel J; Anderson J; Mommeja-Marin H; Rigney A; Rousseau F
Clin Infect Dis; 2005 Sep; 41(5):e45-7. PubMed ID: 16080074
[TBL] [Abstract][Full Text] [Related]
17. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
N'Dri-Yoman T; Anglaret X; Messou E; Attia A; Polneau S; Toni T; Chenal H; Seyler C; Gabillard D; Wakasugi N; Eholié S; Danel C
Antivir Ther; 2010; 15(7):1029-34. PubMed ID: 21041918
[TBL] [Abstract][Full Text] [Related]
18. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
19. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.
Gish RG; Trinh H; Leung N; Chan FK; Fried MW; Wright TL; Wang C; Anderson J; Mondou E; Snow A; Sorbel J; Rousseau F; Corey L
J Hepatol; 2005 Jul; 43(1):60-6. PubMed ID: 15922478
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
Osborn MK; Guest JL; Rimland D
HIV Med; 2007 Jul; 8(5):271-9. PubMed ID: 17561872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
